ROCKVILLE, Md., July 28, 2008 (PRIME NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF) today announced that David F. Counts Ph.D., a leading pharmacologist and medical researcher who discovered the Company’s anti-inflammatory peptide, CT-112, has been retained as a consultant to assist the Company with the further development of the peptide, as the Company prepares to file an Investigational New Drug (IND) submission with the FDA and move into a Phase I Clinical trial. Dr. Counts discovered the anti-inflammatory properties of the CT-112 peptide in the mid 90s during his research of platelet derived growth factors, which contributed to the development of the Company’s AutoloGel(tm) System. Dr. Counts will be working with Dr. Peter Clausen, a leading biochemist, who was also recently retained by the Company to oversee the CT-112 development effort.
